Salubris Pharmaceuticals' SAL0137 drug candidate approved for clinical trials

Shenzhen Salubris Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SAL0137. This innovative small molecule drug aims to treat elevated lipoprotein(a) [Lp(a)], an independent risk factor for various cardiovascular diseases, including coronary heart disease, ischemic stroke, and peripheral vascular disease. Pre-clinical studies indicate SAL0137 holds promising potential.

The company's receipt of the "Clinical Trial Approval Notice" for SAL0137 marks a pivotal development. If successfully developed and approved, SAL0137 could offer a new treatment option for patients, addressing unmet clinical needs and enriching Salubris Pharmaceuticals' portfolio of innovative products in the chronic disease sector.

Shenzhen Salubris Pharmaceuticals will proceed with clinical trials in accordance with national drug registration regulations. The company acknowledges the inherent long development cycles and high risks associated with pharmaceutical R&D, and states that this development is not expected to significantly impact company performance in the short term.